Related Experiment Video
Updated: Feb 7, 2026

Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain
Published on: June 6, 2025
Therapy of Mucormycosis
Nikolaos V Sipsas1, Maria N Gamaletsou2, Amalia Anastasopoulou3
1Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27 Athens, Greece. nsipsas@med.uoa.gr.
Abstract:
Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.
Insights
Management of mucormycosis remains challenging due to limited clinical trial data. Individualized treatment plans are crucial, considering host factors and antifungal properties for this opportunistic infection.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Mucormycosis is a rare, severe opportunistic infection caused by Mucorales fungi.
- Current antifungal agents include amphotericin B, posaconazole, and isavuconazole.
- Lack of prospective randomized clinical trials complicates treatment guidelines.
Purpose of the Study:
- To review the current treatment options for mucormycosis.
- To highlight the uncertainties in managing this infection.
- To emphasize the need for individualized therapeutic strategies.
Main Methods:
- Mini-review of existing literature on mucormycosis treatment.
- Analysis of current antifungal agents and their properties.
- Consideration of host-related factors in disease management.
Main Results:
- Despite new agents, significant uncertainties persist in mucormycosis therapy.
- Disease heterogeneity (host, site, pathogen) necessitates tailored approaches.
- No definitive guidelines exist due to a lack of clinical trial evidence.
Conclusions:
- Individualized mucormycosis management plans are essential.
- Factors to consider include host immunosuppression, comorbidities, diagnostic certainty, infection site, and antifungal drug characteristics.
- Further research, including randomized trials, is needed to establish evidence-based treatment protocols.
Related Concept Videos
Gene Therapy
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy

